Gardasil Getting Pediatric Safety Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite the political noise around the human papillomavirus vaccine, there do not seem to be major new pediatric safety concerns for the Pediatric Advisory Committee to discuss as it reviews Gardasil and 14 other products.
You may also be interested in...
The Hunt For Gardasil Adverse Events: A Preview Of Emerging Social Media Challenges
Bachmann-based brouhaha over Merck's human papilloma virus vaccine underscores the liability risks that firms can face as possible risks for their products are discussed more widely.
Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?
Nov. 17 session is product's third before an FDA advisory committee, but review by CDC's immunization practices panel may be key for utilization and reimbursement.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.